Sphere Medical Holding Regulatory News (SPHR)

For Immediate Release 9 September 2013

Sphere Medical Holding plc

Pelorus 1500 Study at Great Ormond Street Hospital for Children

· Pelorus 1500 pivotal in helping establish new dosing approaches for propofol use in children

· Further research has begun utilising Pelorus 1500 at the University Medical Centre Groningen

Cambridge, UK, 9 September 2013: Sphere Medical Holding plc (AIM: SPHR.L) ("Sphere Medical" or the "Company"), a leading developer of innovative monitoring and diagnostic products for the critical care setting, today announces the completion of a study at Great Ormond Street Hospital for Children ("GOSH") to evaluate the use of Sphere Medical's Pelorus 1500 analyser to monitor accurately propofol levels during paediatric spinal surgery on anaesthetised children.

An initial assessment of the GOSH study indicates that current dosing models can lead to significant variability in the concentration of drug present for this patient group. Detailed analysis of the results is being carried out at GOSH and these data, compiled utilising Pelorus 1500, are intended to be the basis for investigating an improved approach to dosing children in certain surgical procedures.

In addition, Sphere Medical is also collaborating with the Department of Anesthesiology at the University Medical Centre Groningen (UMCG) in the Netherlands and clinicians are investigating the real time adaptation of dosing models to the individual patient using rapid propofol measurements provided by the Pelorus 1500 system. Initial computer modelling to develop the methodology has been completed and Ethics approval has been sought to carry out clinical evaluation trials in adult patients.

The Department of Anesthesiology at (UMCG) is a leading clinical innovator in the field of anaesthetic pharmacology and these clinical trials are planned to start this autumn.

Dr. Stuart Hendry, Chief Executive Officer of Sphere Medical, commenting on today's announcement said:

"This study at Great Ormond Street Hospital for Children provides further evidence that the use of the Pelorus 1500 for the rapid measurement of propofol will ultimately provide personalisation of propofol dosing to the patient during surgery. The work at GOSH and in Groningen is expected to result in the development of the next generation of propofol infusion protocols and control systems which we believe represent a large commercial opportunity for Sphere Medical."

Dr Mike Sury, Consultant Anaesthetist and principal investigator for the study at GOSH, commented:

"Being able to measure propofol levels quickly in the operating theatre may prove useful in finding ways of achieving more accurate control of blood propofol concentrations and help to make propofol anaesthesia more predictable."

About Propofol

Propofol is one of the world's most widely used intravenous anaesthetics, used for the induction and maintenance of general anaesthesia in the operating room and general sedation in the intensive care unit (ICU). Each year, around 12 million patients are admitted to the ICU in the developed world and around 8 million are sedated during treatment. Monitoring of inhaled anaesthetic gases is already a standard of care, but there is no equivalent measurement used for intravenous anaesthetics such as propofol.

For further information, please contact:

Sphere Medical Holding plc Tel: +44 (0)1223 875222

Dr Stuart Hendry, Chief Executive Officer

Matthew Hall, Chief Financial Officer

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Dr Vijay Barathan

Consilium Strategic Communications Tel: +44 (0) 20 7920 2354

Mary-Jane Elliott spheremedical@consilium-comms.com

Amber Bielecka

Matthew Neal

Notes for Editors

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside. Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

Sphere Medical has a number of partnerships with industry leading medical device companies with strategic investments such as Ortho-Clinical Diagnostics, Inc. and Sorin Group.

For further information, please visit www.spheremedical.com